- Home
- EXAS vs MDGL Comparison
EXAS vs MDGL Comparison
Compare EXAS & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXAS
- MDGL
- Stock Information
- Founded
- EXAS 1995
- MDGL 2011
- Country
- EXAS United States
- MDGL United States
- Employees
- EXAS N/A
- MDGL N/A
- Industry
- EXAS Medical Specialities
- MDGL Biotechnology: Pharmaceutical Preparations
- Sector
- EXAS Health Care
- MDGL Health Care
- Exchange
- EXAS Nasdaq
- MDGL Nasdaq
- Market Cap
- EXAS 11.0B
- MDGL 9.6B
- IPO Year
- EXAS N/A
- MDGL N/A
- Fundamental
- Price
- EXAS $100.87
- MDGL $549.26
- Analyst Decision
- EXAS Strong Buy
- MDGL Strong Buy
- Analyst Count
- EXAS 18
- MDGL 13
- Target Price
- EXAS $72.44
- MDGL $539.00
- AVG Volume (30 Days)
- EXAS 7.2M
- MDGL 428.3K
- Earning Date
- EXAS 11-03-2025
- MDGL 11-04-2025
- Dividend Yield
- EXAS N/A
- MDGL N/A
- EPS Growth
- EXAS N/A
- MDGL N/A
- EPS
- EXAS N/A
- MDGL N/A
- Revenue
- EXAS $3,082,033,000.00
- MDGL $740,640,000.00
- Revenue This Year
- EXAS $16.68
- MDGL $395.75
- Revenue Next Year
- EXAS $12.36
- MDGL $65.73
- P/E Ratio
- EXAS N/A
- MDGL N/A
- Revenue Growth
- EXAS 14.47
- MDGL 864.21
- 52 Week Low
- EXAS $38.81
- MDGL $265.00
- 52 Week High
- EXAS $101.87
- MDGL $577.90
- Technical
- Relative Strength Index (RSI)
- EXAS 91.11
- MDGL 68.83
- Support Level
- EXAS $66.00
- MDGL $505.00
- Resistance Level
- EXAS $69.08
- MDGL $577.90
- Average True Range (ATR)
- EXAS 3.80
- MDGL 30.54
- MACD
- EXAS 2.49
- MDGL 7.06
- Stochastic Oscillator
- EXAS 97.30
- MDGL 82.13
About EXAS Exact Sciences Corporation
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.